scholarly journals Significant efficacy and well safety of apatinib in an advanced liver cancer patient: a case report and literature review

Oncotarget ◽  
2017 ◽  
Vol 8 (12) ◽  
pp. 20510-20515 ◽  
Author(s):  
Peisi Kou ◽  
Yan Zhang ◽  
Wenbo Shao ◽  
Hui Zhu ◽  
Jingze Zhang ◽  
...  
Keyword(s):  
Case Report ◽  
Liver Cancer ◽  
Literature Review ◽  
Cancer Patient ◽  
Significant Efficacy ◽  
Liver Cancer Patient

scholarly journals A lung cancer patient with deep vein thrombosis:a case report and literature review

BMC Cancer ◽  
2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Yungu Chen ◽  
Yiu Sing Tsang ◽  
Xiaoxia Chou ◽  
Jiong Hu ◽  
Qing Xia
Keyword(s):  
Lung Cancer ◽  
Case Report ◽  
Literature Review ◽  
Cancer Patient ◽  
Lung Cancer Patient ◽  
Deep Vein

scholarly journals Recurrent Metastatic Penile Cancer Patient with Positive PD-L1 Expression Obtained Significant Benefit from Immunotherapy: A Case Report and Literature Review

2020 ◽  
Vol Volume 13 ◽  
pp. 3319-3324
Author(s):  
Xiangyu Su ◽  
Jing Zhang ◽  
Chenchun Fu ◽  
Mingzhe Xiao ◽  
Cailian Wang
Keyword(s):  
Case Report ◽  
Literature Review ◽  
Cancer Patient ◽  
Penile Cancer ◽  
Significant Benefit

61 A panel of pediatric liver cancer patient-derived xenografts to improve stratification of children with hepatoblastoma

2014 ◽  
Vol 50 ◽  
pp. 25
Author(s):  
M. Fabre ◽  
D. Nicolle ◽  
A. Gorse ◽  
O. Déas ◽  
C. Mussini ◽  
...  
Keyword(s):  
Liver Cancer ◽  
Cancer Patient ◽  
Pediatric Liver ◽  
Liver Cancer Patient

Abstract 2797: Liver cancer patient-derived xenografts to improve disease management in childhood and adolescence: perspectives and challenges of personalized medicine.

2013 ◽  
Author(s):  
Stefano Cairo ◽  
Aurore Gorse ◽  
Delphine Nicolle ◽  
Erwan Selingue ◽  
Frédéric Gauthier ◽  
...  
Keyword(s):  
Personalized Medicine ◽  
Disease Management ◽  
Liver Cancer ◽  
Cancer Patient ◽  
Childhood And Adolescence ◽  
Liver Cancer Patient

scholarly journals Dermatological adverse effects in a cancer patient treated with an EGFR inhibitor. Case report and literature review

2018 ◽  
Vol 105 (5) ◽  
pp. 632-638
Author(s):  
Magdalena Korzycka ◽  
Agnieszka J. Osmola-Mańkowska ◽  
Monika Bowszyc-Dmochowska ◽  
Ryszard W. Żaba ◽  
Zygmunt Adamski
Keyword(s):  
Case Report ◽  
Literature Review ◽  
Adverse Effects ◽  
Cancer Patient ◽  
Egfr Inhibitor

ROS new function for ECT imaging observation of sustained 99mTC-labeled cytarabine in liver cancer patient with hydrogen peroxide.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e15568-e15568
Author(s):  
Guoqin Zheng ◽  
Yan Han ◽  
Jian Zhang ◽  
Bian Li ◽  
Dong Chen ◽  
...  
Keyword(s):  
Hydrogen Peroxide ◽  
Liver Cancer ◽  
Cancer Patient ◽  
Tumor Cells ◽  
Retention Rate ◽  
Acquisition Time ◽  
Emission Computed Tomography ◽  
Drug Retention ◽  
Liver Cancer Patient ◽  
Long Time

e15568 Background: To investigate the sustaining time of 99mTc labeled cytarabine in the tumor of liver cancer patients by ROS under ECT imaging instrument. Methods: A liver cancer patient with 2 lesions in the liver was enrolled in this study. After obtaining informed consent and excluding relevant contraindications, two tumors in the liver of the patient were guided by single photon emission computed tomography (ECT). Injecting the drug, the tumor was injected with 99m TC-labeled cytarabine solution as control, the tumor was injected with 99m TC-labeled cytarabine + hydrogen peroxide solution (ROS) as experimental, and the two tumor masses were detected by ECT imaging, with an intensity of 1h as background. The drug retention rate was calculated by caculated of deduction of the baseline (minus background) at 1h, 3h, and 23h. Results: The patient was detected by ECT on the right laid down position. The area of the region of interest was 679 account by Gama detector, and the background level of the liver was 494 account. The acquisition time was about 400 seconds as a standard acquisition. The ECT imaging showed that the labeling rate of 99mTC-labeled cytarabine was about 100%. The drug of 99mTC-labeled cytarabineretentionrates in tumor lesions with ROS at 1 hours, 3 hours, and 23 hours were 97.83%, 81.63%, and 60.72%, respectively; the drug retention rates in tumor lesions without ROS at 1 hours, 3 hours, and 23 hours were 44.74%, 15.87%, and 0, respectively. Conclusions: The ROS can hold drug in the tumor long time after the intratumoral injection of drugs with ROS whichoxidant with the extracellular matrix and interstitial of the tumor to cause degeneration and deformation so that drug of Ara-C sustaining in tumor for a long time, and the tumor cells are also degenerated and necrotic and died, so that high concentrations of cytarabine are embedded between the denatured tumor tissues and cells. The drug slowly released from the inside to the outside to kill tumor cells. IT is further confirmed that the ROS is a sustained release agent intratumorally injection and it can significantly increase the residence time of 99mTc-labeled cytarabine in the tumor, prolong the drug action time of cytarabine, and improve the effect of killing tumor cells.

Sign in / Sign up

Export Citation Format

Share Document